Reduced costs for staphylococcus aureus carriers treated prophylactically with mupirocin and chlorhexidine in cardiothoracic and orthopaedic surgery by Rijen, M.M.L. (Miranda) van et al.
Reduced Costs for Staphylococcus aureus Carriers
Treated Prophylactically with Mupirocin and
Chlorhexidine in Cardiothoracic and Orthopaedic
Surgery
Miranda M. L. van Rijen1*., Lonneke G. M. Bode2., Diane A. Baak3, Jan A. J. W. Kluytmans1,4,
Margreet C. Vos2
1 Laboratory for Microbiology and Infection Control, Amphia Hospital, Breda, The Netherlands, 2Department of Medical Microbiology and Infectious Diseases, Erasmus
University Medical Centre, Rotterdam, The Netherlands, 3 Business Information Centre, Amphia Hospital, Breda, The Netherlands, 4Department of Medical Microbiology
and Infection Control, VU University Medical Centre, Amsterdam, The Netherlands
Abstract
Background: A multi centre double-blind randomised-controlled trial (M-RCT), carried out in the Netherlands in 2005–2007,
showed that hospitalised patients with S. aureus nasal carriage who were treated prophylactically with mupirocin nasal
ointment and chlorhexidine gluconate medicated soap (MUP-CHX), had a significantly lower risk of health-care associated
S. aureus infections than patients receiving placebo (3.4% vs. 7.7%, RR 0.42, 95% CI 0.23–0.75). The objective of the present
study was to determine whether treatment of patients undergoing elective cardiothoracic or orthopaedic surgery with
MUP-CHX (screen-and-treat strategy) affected the costs of patient care.
Methods: We compared hospital costs of patients undergoing cardiothoracic or orthopaedic surgery (n = 415) in one of the
participating centres of the M-RCT. Data from the ‘Planning and Control’ department were used to calculate total hospital
costs of the patients. Total costs were calculated including nursing days, costs of surgery, costs for laboratory and
radiological tests, functional assessments and other costs. Costs for personnel, materials and overhead were also included.
Mean costs in the two treatment arms were compared using the t-test for equality of means (two-tailed). Subgroup analysis
was performed for cardiothoracic and orthopaedic patients.
Results: An investigator-blinded analysis revealed that costs of care in the treatment arm (MUP-CHX, n = 210) were on
average J1911 lower per patient than costs of care in the placebo arm (n = 205) (J8602 vs. J10513, p = 0.01). Subgroup
analysis showed that MUP-CHX treated cardiothoracic patients cost J2841 less (n = 280, J9628 vs J12469, p = 0.006) and
orthopaedic patients J955 less than non-treated patients (n = 135, J6097 vs J7052, p = 0.05).
Conclusions: In conclusion, in patients undergoing cardiothoracic or orthopaedic surgery, screening for S. aureus nasal
carriage and treating carriers with MUP-CHX results in a substantial reduction of hospital costs.
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Introduction
Staphylococcus aureus (S. aureus) nasal carriage rates range from
about 20 to 50%, depending on the population and the definitions
used [1–3]. Infections with S. aureus can develop after disruption of
the skin barrier, for example after an incision has been made
during surgery. It has been shown that in surgical patients,
nosocomial S. aureus infections are mainly caused by their own
S. aureus strain (endogenous infection) [4–7]. S. aureus nasal
carriage is now considered to be a well-defined risk factor for
subsequent infection in various groups of patients, especially those
on dialysis; with cirrhosis of the liver; undergoing surgery; and with
intravascular devices or in intensive care [3,8]. This raised the
hypothesis that eradication of S. aureus from the nose would result
in fewer S. aureus infections in these groups of patients. Many
studies have evaluated this effect in the past decades. Until 2010,
only a few studies were double-blind randomised-controlled trials
(RCT) [5,9–16]. In these studies various patient populations were
treated intranasally with mupirocin, an antibiotic nasal ointment.
None of these studies found a significantly reduced number of
S. aureus infections compared to placebo treatment. However, in
most of these studies, both S. aureus nasal carriers and non-carriers
were treated. Perl et al were the first to perform a subgroup
analysis on carriers only and showed that 4.0 percent of mupirocin
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treated patients with nasal carriage of S. aureus suffered from
nosocomial S. aureus infections, compared to 7.7 percent of those
who received placebo (p = 0.02). Subsequently, all data pertaining
to carriers in the above mentioned RCTs were combined in
a systematic review, which showed that carriers who were treated
with mupirocin before surgery had 44% less chance of developing
a nosocomial S. aureus infections than patients receiving placebo
[17].
Based on these findings a multi-centre double-blind rando-
mised-controlled trial (M-RCT) was performed in which only
S. aureus nasal carriers were included [6]. This study showed that
patients treated with mupirocin and chlorhexidine gluconate
medicated soap (MUP-CHX) had a significantly lower risk of
health-care related S. aureus infections than patients receiving
placebo (3.4% vs. 7.7%, RR 0.42, 95% CI 0.23–0.75).
The objective of the present study was to compare hospital costs
of patients treated with MUP-CHX (screen-and-treat strategy) to
those of patients treated with placebo (comparable to a non-
screen-and-treat strategy), in patients undergoing elective cardio-
thoracic or orthopaedic surgery.
Methods
In the M-RCT, performed in three university hospitals and two
teaching hospitals, patients who were admitted to departments of
surgery and internal medicine were screened for S. aureus nasal
carriage [6]. The present cost analysis was carried out for patients
of only the Amphia hospital, a teaching hospital which serves
a population of approximately 440,000 inhabitants. During the
study period, on average 41,534 patients were admitted annually
to this hospital with 271,528 in-patient days per year (mean
number over the period 2005 to 2007, excluding day care).
A total of 415 patients admitted for elective cardiothoracic and
orthopaedic surgery in this hospital participated in the M-RCT.
Cardiothoracic patients (n = 280) underwent Coronary Artery
Bypass Grafting (CABG) operations with or without valve
replacement (n = 88 and n= 150, respectively) or other cardiotho-
racic surgery (n = 3). In 39 patients the nature of cardiothoracic
surgery was not further specified. Orthopaedic patients (n = 135)
underwent knee replacement (n = 45), hip replacement (n = 50),
spinal surgery (n = 28) or other orthopaedic procedures (n = 12)
(see Table S1).
An investigator-blinded analysis was carried out to compare all
hospital costs incurred between start of admission and the end of
follow-up (42 days after discharge) for patients in both treatment
groups (MUP-CHX vs. placebo). Costs were analysed for the total
follow up period, as well as per admission (categorised as the first,
second, third admission etc) during this period. Actual total
hospital costs per included patient were retrieved from the data
files of ‘Planning and Control’ (P&C) department of the hospital
(figure 1). Since the study medication (MUP-CHX) was supplied
for free during the study, the cost of this medication was added to
the costs of patients treated with MUP-CHX. Screening costs were
already included in the laboratory tests performed; for the placebo
group, screening costs were subtracted from total costs because this
study arm represents the strategy without screening or treatment.
For the period between discharge and the end of follow-up, all
costs made during re-admissions or costs for outpatient visits were
included. Community costs were not estimated. All costs for
readmissions and secondary surgical procedures in this period
were included. Physicians’ fees were not registered in the P&C
data file, so these costs could not be included in this analysis.
Mean costs in both treatment arms were compared using the t-
test for equality of means (two-tailed). Statistical significance was
accepted when p,0.05. Subgroup analysis was performed for
cardiothoracic and orthopaedic patients.
The average Euro to US dollar exchange rate during the study
period was 1.35.
Results
Mean total hospital costs for a MUP-CHX treated patient
undergoing cardiothoracic or orthopaedic surgery were signifi-
cantly lower than costs for a placebo treated patient (J8602 vs.
J10513, p = 0.01) (table 1). Table 1 shows that mean costs per
patient for all individual categories, i.e. costs for nursing days,
surgery, functional assessments, and laboratory and radiological
tests during the first two admissions combined, were higher in the
placebo group than in the MUP-CHX treated group. During the
first admission significant differences between the treatment
groups were found only in costs for nursing days. For the second
admission, costs for nursing days, costs made during surgery, costs
for laboratory and radiological tests, and functional assessments
were found to be significantly lower in the treatment arm.
Subgroup analysis showed that the mean expenses for MUP-CHX
treated cardiothoracic patients were J2841 lower than for non
treated cardiothoracic patients (J9628 vs. J12469, p= 0.006) and
J955 lower for MUP-CXH treated orthopaedic patients com-
pared to non treated orthopaedic patients (J6097 vs. J7052,
p = 0.05) (figure 2).
The distribution of costs depicted in the box plot (figure 1)
shows that the difference in costs between the two treatment
groups is mainly caused by a number of patients with higher costs
in the placebo group compared to the MUP-CHX group. This
holds true for both the cardiothoracic and the orthopaedic
patients. Four of these patients suffered from a deep endogenous
S. aureus infection.
In the placebo group, 13 of 205 patients acquired a S. aureus
infection in the hospital, compared to 3 of 210 patients in the
MUP-CHX group (p = 0.01). The hospital costs for uninfected
patients varied between J1986 and J72704, with a mean of
J8834 and a median of J7898. For infected patients these ranged
between J3693 and J99512, with a mean of J27313 and
a median of J19707 (p,0.001).
Discussion
This study shows that mean hospital costs for nasal S. aureus
carriers undergoing elective cardiothoracic or orthopaedic surgery
receiving treatment with MUP-CHX were significantly lower than
for patients without treatment (placebo). This was caused by
significantly higher hospital costs for S. aureus infected patients
(p,0.001) in combination with significantly more S. aureus infected
patients in the placebo group (p = 0.01) (see Table S1). It must be
noted that for cardiothoracic surgery, nine of twenty patients with
highest costs suffered from a deep S. aureus infection, i.e. eight cases
of mediastinitis after CABG with/without valve replacement, and
one case of pericarditis after pericardiectomy. Thus, almost half of
the patients incurring the highest costs suffered from a deep
S. aureus infection. This explains why prevention of these infections
by application of MUP-CHX results in a significant cost
reduction. In orthopaedic surgery, two deep-seated infections
developed, one after total knee replacement and one after total hip
revision. Costs of these two patients were found in of the group of
25 patients with highest costs.
To put these results into perspective this screen-and-treat
strategy for S. aureus nasal carriers undergoing cardiothoracic or
orthopaedic surgery would save the Amphia hospital approxi-
mately J 1,500,000 per year.
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The S. aureus screen-and-treat strategy was already shown to
result in a higher quality of patient care by reducing the number of
S. aureus infections [6]. Lower costs and safer patient care were also
found in the subgroups of patients undergoing cardiothoracic
surgery or orthopaedic surgery. Other authors already estimated
that introduction of a screen-and-treat strategy would result in
lower hospital costs [18–20]. For example, the study by
Wassenberg et al was based on the actual hospital costs for
patients with deep-seated prosthetic joint and cardiac surgery
infections in combination with the evidence-based assumptions
that non-carriers have six times less chance of acquisition of such
infections than S. aureus carriers [15], and that the relative risk of
deep-seated S. aureus infections after MUP-CHX treatment was
0.21 compared to placebo [6]. The strength of the present study is
it is the first to calculate the real hospital costs based on the data
files of the P&C department. The analyses of this study were
performed in an investigator-blinded fashion and patients were
randomly assigned to either placebo or treatment arms [6].
The results of the present study are useful for hospitals that are
planning to implement the screen-and-treat strategy but which
need more evidence to convince their financial management.
Some hospitals prefer to implement the treat-all strategy instead of
the screen-and-treat strategy, mainly for two reasons. They argue
that first, treating all patients is cheaper than screening all patients
and subsequently treating nasal S. aureus carriers [16,18] and
second, this procedure is more convenient for the HCWs. Both
Figure 1. Calculation of total costs incurred by the hospital for an individual patient in a particular department.
doi:10.1371/journal.pone.0043065.g001
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a screen-and-treat and a treat-all strategy have been proven
cheaper for the hospital than no screening or treatment at all. Of
course, this treat-all strategy is cheaper than the screen-and-treat
strategy, because the costs of the screening test, which is more
expensive than the costs for mupirocin ointment and antibacterial
soap, can be omitted. Wassenberg showed that treating all patients
without screening would result in a saving of J7339 per life year
gained, as compared to J3330 if only identified carriers were
treated [18]. The low price and safety of mupirocin will easily lead
to non-prudent use of this important antimicrobial agent.
However, this treat-all strategy is associated with a high rate of
unnecessary and thus unethical treatments that increase the
likelihood of the development of resistance [21]. Mupirocin
resistance will obviously lead to failure of S. aureus decolonisation
strategies. Cautious use of mupirocin is likely to maintain the
mupirocin resistance at a low level, thus preserving its efficacy.
The aim of the prophylactic treatment is not to eradicate S. aureus
forever but to result in short-term S. aureus eradication of
approximately a month to prevent postoperative S. aureus wound
infections. It was shown that combined low-level mupirocin and
genotypic chlorhexidine resistance significantly increases the risk
of persistent methicillin-resistant S. aureus (MRSA) carriage after
decolonisation therapy [22]. Although the MRSA rates in the
Netherlands are still low [23], it is useful to monitor for mupirocin
and chlorhexidine resistance in hospitals using a screen-and-treat
strategy for S. aureus carriage. In our hospital, MUP-CHX
has been used for over 15 years in cardiothoracic surgery and,
to date, mupirocin resistance after treatment has not been found
(unpublished data).
In order to resolve practical issues, patients planned for elective
cardiothoracic or orthopaedic surgery should be screened pre-
operatively in the outpatients department, and for those found to
be a carrier, a prescription should be sent to the community
pharmacy by the physician, so that patients can start treatment at
home prior to admission. This treatment can be continued and
finished in the hospital. For patients admitted without prior
screening, rapid testing using molecular tools is an option,
available 24 hours a day for optimal patient care.
The results of this study clearly show a financial benefit
associated with the screen-and-treat strategy in elective cardiotho-
racic and orthopaedic surgery. Based on the nasal S. aureus carriage
rate of 20% we found in the study, per thousand surgical patients
approximately J400,000 could be saved. Worldwide millions of
surgical procedures are performed each year, so huge numbers of
patients would benefit from this strategy and this would be
accompanied by large savings. The US Centers for Disease
Control have now included this strategy in their top recommenda-
tions for safer health care (http://www.cdc.gov/HAI/prevent/
top-cdc-recs-prevent-hai.html). For other surgical procedures or
non-surgical hospitalisations, debate is still open on the economical
impact of such a strategy.
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